Skip to the main content

Review article

https://doi.org/10.15644/asc59/4/9

Impaired Gustation in Liver Diseases: A Comprehensive Narrative Literature Review

Aleksandra Kędziora-Ciechańska ; Department of Oral Medicine, Medical University of Lublin, Lublin, Poland; Doctoral School of the Medical University of Lublin, Lublin, Poland
Krystian Ciechański ; Department of Gastroenterology, Regional Specialist Hospital, Lublin, Poland; Department of Toxicology, Medical University of Lublin, Lublin, Poland; Doctoral School of the Medical University of Lublin, Lublin, Poland *
Renata Chałas ; Department of Oral Medicine, Medical University of Lublin, Lublin, Poland

* Corresponding author.


Full text: english pdf 329 Kb

page 426-439

downloads: 467

cite

Full text: croatian pdf 329 Kb

page 426-439

downloads: 88

cite


Abstract

Objective: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the fastestgrowing liver disorders worldwide. It is driven by obesity and type 2 diabetes. Taste perception plays a key role in appetite regulation and nutrition, also influencing other liver diseases progression. This review summarizes past and current evidence on taste disorders in liver diseases and their clinical implications. Materials and Methods: A narrative review of PubMed, Web of Science, Google Scholar, and ResearchGate databases was conducted using selected MeSH terms. Results: Taste disturbances have been reported in viral hepatitis, cirrhosis, Wilson’s disease, amebic liver abscesses, and NAFLD/MASLD, as well as in nutritional deficiencies (zinc, magnesium, vitamin A, branchedchain amino acids). Dysgeusia was linked to reduced appetite, sarcopenia, malnutrition, altered food preferences, and obesity risk in MASLD. Taste impairments worsen with liver dysfunction progression. Several drugs (e.g., interferon, metronidazole) contribute to dysgeusia. Zinc deficiency was the most consistent factor. Glucagon-like peptide-1 (GLP-1) receptor modulators, affecting appetite and sweet/umami perception, appear promising in MASLD therapy. Conclusions: Taste disorders are prevalent and still under-recognized in populations with liver diseases. The cause of these disorders remains unclear. Most of available studies affecting nutrients deficiencies are outdated. More research targeting molecular pathways of taste modulation (e.g., GLP-1 receptors), as well as determining the prevalence and clinical consequences of dysgeusia in specific liver disease stages is needed to better understand how micronutrient deficiencies and medications affect taste disorders.

Keywords

Liver diseases; Dysgeusia; Taste perception; Taste disorders; Zinc; MASLD

Hrčak ID:

341920

URI

https://hrcak.srce.hr/341920

Publication date:

26.12.2025.

Article data in other languages: croatian

Visits: 920 *